• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-3/A filed by Vivani Medical Inc. (Amendment)

    5/2/24 4:42:48 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $VANI alert in real time by email
    S-3/A 1 g084213_s3.htm S-3/A

    As filed with the Securities and Exchange Commission on May 2, 2024

     

    Registration Statement No. 333-278869

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    AMENDMENT NO. 1 

    TO

    FORM S-3

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    VIVANI MEDICAL, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   02-0692322

    (State or other jurisdiction of

    incorporation or organization) 

     

    (I.R.S. Employer

    Identification Number)

     

    1350 S. Loop Road 

    Alameda, California 94502

    (415) 506-8462

     

    (Address, including zip code, and telephone number, including area code, of the registrant’s principal executive offices)

     

    Adam Mendelson, Ph.D.

    Chief Executive Officer

    Vivani Medical, Inc.

    1350 S. Loop Road

    Alameda, California 94502

    (415) 506-8462

     

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copy to:

     

    Deepa M. Rich

    Adam V. Johnson

    Jacqueline R. Kaufman

    Goodwin Procter LLP

    620 8th Avenue

    New York NY 10018

    (212) 813-8800

     

     

     

     

    Approximate date of commencement of proposed sale to the public: From time to time or at one time as determined by the Registrant after the effective date of this registration statement.

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act of 1933, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Securities Exchange Act of 1934:

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

     

    The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said section 8(a), may determine. 

     

     

     

     

    EXPLANATORY NOTE

     

    This Amendment No. 1 (this “Amendment”) to the Registration Statement on Form S-3 (File No. 333-278869) of Vivani Medical, Inc. (the “Company”), originally filed on April 22, 2024 (the “Registration Statement”), is being filed solely to file a revised consent of BPM LLP, the Company’s independent registered public accounting firm (the “Auditor’s Consent”), as Exhibit 23.1 to the Registration Statement. Accordingly, this Amendment consists only of the cover page, this explanatory note, Item 16 of Part II of the Registration Statement and the Auditor’s Consent filed herewith as Exhibit 23.1. This Amendment does not modify any content of the prospectus contained in Part I or the balance of Part II of the Registration Statement which are hereby omitted.

     

     

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN THE PROSPECTUS

     

    Item 16.   Exhibits

     

    Exhibit No.   Description
       
    1.1*   Form(s) of underwriting agreement(s).
         
    1.2***   Open Market Sale AgreementSM , dated April 22, 2024, between the Company and Jefferies LLC.
       
    3.1   Certificate of Incorporation of Vivani Medical, Inc., filed with the Secretary of State of Delaware and effective, July 6, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 10, 2023).
       
    3.2   Bylaws of Vivani Medical, Inc. (a Delaware Corporation) effective July 6, 2023 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the SEC on July 10, 2023).
       
    4.1   Specimen Common Stock Certificate (Incorporated by reference to Exhibit 4.1 to the Company’s  Annual Report on Form 10-K filed on March 26, 2024 (File No. 001-36747)).
         
    4.2   Description of Capital Stock (Incorporated by reference to Exhibit 4.5 to the Company’s Annual Report on Form 10-K filed on March 26, 2024 (File No. 001-36747)).
       
    4.3***   Form of indenture for senior debt securities and the related form of senior debt security.
       
    4.4***   Form of indenture for subordinated debt securities and the related form of subordinated debt security.
       
    4.5*   Form of Certificate of Designations.
       
    4.6*   Form of Warrant Agreement.
       
    4.7*   Form of Unit Certificate.
       
    4.8*   Form of Preferred Stock Certificate.
       
    5.1***   Opinion of Goodwin Procter LLP.
         
    5.2***   Opinion of Goodwin Procter LLP relating to sales agreement prospectus.
         
    23.1**   Consent of BPM LLP, Independent Registered Public Accounting Firm
       
    23.2***   Consent of Goodwin Procter LLP (included in Exhibit 5.1 hereto).
       
    24.1**   Power of Attorney (included in the signature pages to this registration statement).
       
    25.1†   Form T-1 Statement of Eligibility of Trustee for Senior Indenture under the Trust Indenture Act of 1939.
       
    25.2†   Form T-1 Statement of Eligibility of Trustee for Subordinated Indenture under the Trust Indenture Act of 1939.
         
    107***   Filing Fee Table.

     

    * To be filed by amendment or as exhibit(s) to a Current Report of the Registrant on Form 8-K and incorporated herein by reference, as applicable.
    ** Filed herewith.
    *** Previously filed.
    † To be filed pursuant to Section 305(b)(2) of the U.S. Trust Indenture Act of 1939, as applicable.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended (the “Securities Act”), the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Alameda, State of California, on May 2, 2024. 

         
      VIVANI MEDICAL, INC.
         
      By:

    /s/ Adam Mendelsohn

      Name: Adam Mendelsohn
      Title: Chief Executive Officer

     

    Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dated indicated.

     

    Name   Title   Date
             
    /s/ Adam Mendelsohn   Chief Executive Officer and Director    May 2, 2024
    Adam Mendelsohn   (Principal Executive Officer)    
             
    /s/ Brigid Makes   Chief Financial Officer    May 2, 2024
    Brigid Makes   (Principal Financial and Accounting Officer)    
             
    *   Chairman of the Board    May 2, 2024
    Gregg Williams        
             
    *   Director    May 2, 2024
    Aaron Mendelsohn        
             
    *   Director    May 2, 2024
    Dean Baker        
             
    *   Director    May 2, 2024
    Alexandra Larson        
             
    *   Director    May 2, 2024
    Daniel Bradbury        
             
    * By: /s/ Adam Mendelsohn  
      as Attorney-in-Fact  

      

     

    Get the next $VANI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VANI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VANI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

    Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology  Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. ("Cortigent"), its wholly-owned subsidiary developing brain implant de

    1/29/26 7:30:00 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Vivani Medical, Inc. Announces Closing of Common Stock Offering

    ALAMEDA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and a concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. Gross proceeds from the two transactions were approximately $4.5 million, before deducting fees and offering expens

    1/27/26 4:05:00 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Vivani Medical, Inc. Announces Pricing of Common Stock Offering

    ALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pricing of a best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. The registered offering and the private placement were priced "at-the-market" under the rules and regulations of The Nasdaq Stock Market LLC

    1/25/26 11:36:27 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Gregg bought $1,999,999 worth of shares (1,351,351 units at $1.48) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/28/26 10:01:22 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,983,334 worth of shares (1,737,765 units at $1.14) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/20/26 9:00:37 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Bradbury Daniel

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/5/26 6:50:12 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Gregg bought $1,999,999 worth of shares (1,351,351 units at $1.48) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/28/26 10:01:22 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,983,334 worth of shares (1,737,765 units at $1.14) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/20/26 9:00:37 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Mendelsohn Aaron gifted 20,000 shares and bought $24,600 worth of shares (20,000 units at $1.23) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    12/31/25 9:00:39 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    SEC Filings

    View All

    Vivani Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vivani Medical, Inc. (0001266806) (Filer)

    1/27/26 4:11:14 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Vivani Medical Inc.

    424B5 - Vivani Medical, Inc. (0001266806) (Filer)

    1/27/26 6:01:48 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Vivani Medical Inc.

    10-Q - Vivani Medical, Inc. (0001266806) (Filer)

    11/13/25 8:10:56 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Financials

    Live finance-specific insights

    View All

    Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders

    Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind Cortigent's new Orion® artificial vision system, developed to treat blindness caused by common conditions, has successfully completed a 6-year Early Feasibility Study Cortigent is developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke Vivani to sharpen focus on development of miniature, ultra long-acting GLP-1 implants for weight loss management and treatment of type 2 diabetes with once or twice-year

    9/17/25 8:30:00 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Leadership Updates

    Live Leadership Updates

    View All

    Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

    Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable accelerated development of NPM-139 while securing financial position into the second half of 2026 Vivani to spin off Cortigent, Inc., a division of the Company that develops brain implant devices to help patients recover critical body functions, as an independent publicly traded company ALAMEDA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company

    8/13/25 4:20:00 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Vivani Medical Inc. (Amendment)

    SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)

    5/1/23 8:42:07 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by Vivani Medical Inc.

    SC 13D - Vivani Medical, Inc. (0001266806) (Subject)

    4/25/23 5:28:48 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care